Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Optinose (NASDAQ:OPTN), a pharmaceutical company specializing in treatments for ear, nose, and throat (ENT) and allergy patients, has announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Optinose (NASDAQ:OPTN), a pharmaceutical company specializing in treatments for ear, nose, and throat (ENT) and allergy patients, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The company's management team will deliver a presentation on September 9, 2024, at 10:00 a.m. ET, providing a comprehensive overview of the company and updates on its business operations.
Investors and interested parties can access a live webcast of the presentation through the Investors page on the Optinose website. For those unable to attend the live event, a replay of the webcast will be available for 30 days following the conference.
Details
News Market Reaction – OPTN
The recorded move for OPTN in the trading session of this news was +0.56%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
YARDLEY, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024 at 10:00 a.m. ET.
To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website.
A replay of the webcast will be available for 30 days following the conclusion of the event.
About Optinose
Optinose is a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. To learn more, please visit www.optinose.com or follow us on X and LinkedIn.
Optinose Investor Contact
Jonathan Neely
jonathan.neely@optinose.com
267.521.0531
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.